11/12
05:31 pm
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $115.00 price target on the stock.
Low
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $115.00 price target on the stock.
11/12
06:30 am
nuvl
Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results
Low
Report
Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results
10/24
07:16 am
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $100.00 price target on the stock.
Low
Report
Nuvalent, Inc. (NASDAQ: NUVL) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $100.00 price target on the stock.
10/4
03:12 pm
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its price target raised by analysts at JPMorgan Chase & Co. from $100.00 to $125.00. They now have an "overweight" rating on the stock.
Low
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its price target raised by analysts at JPMorgan Chase & Co. from $100.00 to $125.00. They now have an "overweight" rating on the stock.
9/18
04:05 pm
nuvl
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
Low
Report
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
9/18
03:47 pm
nuvl
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally? [Yahoo! Finance]
Low
Report
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally? [Yahoo! Finance]
9/18
07:31 am
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong sell" rating.
Low
Report
Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong sell" rating.
9/17
02:13 am
nuvl
Nuvalent announces pricing of $500M upsized stock offering [Seeking Alpha]
Medium
Report
Nuvalent announces pricing of $500M upsized stock offering [Seeking Alpha]
9/16
10:29 pm
nuvl
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock [Yahoo! Finance]
Medium
Report
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock [Yahoo! Finance]
9/16
10:23 pm
nuvl
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
Medium
Report
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
9/16
01:06 pm
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its price target raised by analysts at Wedbush from $99.00 to $115.00. They now have an "outperform" rating on the stock.
Medium
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its price target raised by analysts at Wedbush from $99.00 to $115.00. They now have an "outperform" rating on the stock.
9/16
01:06 pm
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its price target raised by analysts at Guggenheim from $99.00 to $105.00. They now have a "buy" rating on the stock.
Medium
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its price target raised by analysts at Guggenheim from $99.00 to $105.00. They now have a "buy" rating on the stock.
9/16
12:51 pm
nuvl
Stocks making the biggest moves midday: Nuvalent, Alcoa, Sprouts Farmers Market, Apple and more [CNBC]
Medium
Report
Stocks making the biggest moves midday: Nuvalent, Alcoa, Sprouts Farmers Market, Apple and more [CNBC]
9/16
09:13 am
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its price target raised by analysts at BMO Capital Markets from $102.00 to $132.00. They now have an "outperform" rating on the stock.
Medium
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its price target raised by analysts at BMO Capital Markets from $102.00 to $132.00. They now have an "outperform" rating on the stock.
9/16
08:03 am
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its price target raised by analysts at Stifel Nicolaus from $115.00 to $135.00. They now have a "buy" rating on the stock.
Medium
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its price target raised by analysts at Stifel Nicolaus from $115.00 to $135.00. They now have a "buy" rating on the stock.
9/16
07:56 am
nuvl
Nuvalent jumps 19% on $350M equity offering [Seeking Alpha]
Medium
Report
Nuvalent jumps 19% on $350M equity offering [Seeking Alpha]
9/16
07:00 am
nuvl
Nuvalent Announces Public Offering of Common Stock
Medium
Report
Nuvalent Announces Public Offering of Common Stock
9/14
08:14 pm
nuvl
Nuvalent, Inc. (NUVL): Among Hedge Funds' Top Biotech Stock Picks [Yahoo! Finance]
High
Report
Nuvalent, Inc. (NUVL): Among Hedge Funds' Top Biotech Stock Picks [Yahoo! Finance]
9/14
05:00 am
nuvl
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
High
Report
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
9/13
09:58 am
nuvl
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655 [Yahoo! Finance]
Medium
Report
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655 [Yahoo! Finance]
9/13
09:53 am
nuvl
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655
Medium
Report
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655
9/9
08:45 am
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $99.00 price target on the stock.
Low
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $99.00 price target on the stock.
9/9
06:30 am
nuvl
Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles
Low
Report
Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles
9/4
06:15 pm
nuvl
Nuvalent, Inc. (NASDAQ: NUVL) had its price target raised by analysts at JPMorgan Chase & Co. from $90.00 to $100.00. They now have an "overweight" rating on the stock.
Low
Report
Nuvalent, Inc. (NASDAQ: NUVL) had its price target raised by analysts at JPMorgan Chase & Co. from $90.00 to $100.00. They now have an "overweight" rating on the stock.
8/29
11:36 am
nuvl
Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation [Yahoo! Finance]
Low
Report
Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation [Yahoo! Finance]